Cargando…

Early prophylaxis of cardiomyopathy with beta-blockers and angiotensin receptor blockers in patients with Duchenne muscular dystrophy

Detalles Bibliográficos
Autores principales:	Lee, Heirim, Song, Jinyoung, Kang, I-Seok, Huh, June, Yoon, Jin A, Shin, Yong Beom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Pediatric Society 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561187/ https://www.ncbi.nlm.nih.gov/pubmed/35996796 http://dx.doi.org/10.3345/cep.2022.00836

Ejemplares similares

Beta-Blockers, Left and Right Ventricular Function, and In-Vivo Calcium Influx in Muscular Dystrophy Cardiomyopathy
por: Blain, Alison, et al.
Publicado: (2013)

The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
por: Liu, Tao, et al.
Publicado: (2023)

Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study
por: Bourke, John P, et al.
Publicado: (2018)

Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients
por: Cho, Min Ae, et al.
Publicado: (2020)

Beta-Blockers in Pediatric Hypertrophic Cardiomyopathies
por: Östman-Smith, Ingegerd
Publicado: (2014)

Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy
por: Barp, Andrea, et al.
Publicado: (2015)

Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke
por: Zeng, Yuanyuan, et al.
Publicado: (2023)

Predictors of Death in Adults With Duchenne Muscular Dystrophy–Associated Cardiomyopathy
por: Cheeran, Daniel, et al.
Publicado: (2017)

Cardiomyopathy in Duchenne Muscular Dystrophy: A Single-Center Experience
por: Kummitha, Karthikeyan, et al.
Publicado: (2022)

The evolution of electrocardiographic changes in patients with Duchenne muscular dystrophies
por: Yoo, Woo Hyun, et al.
Publicado: (2017)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Current Understanding of Molecular Pathology and Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy
por: van Westering, Tirsa L. E., et al.
Publicado: (2015)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Corticosteroid use and bone health management for Duchenne muscular dystrophy in South Korea
por: Yoon, Jin A, et al.
Publicado: (2022)

An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Reducing sarcolipin expression mitigates Duchenne muscular dystrophy and associated cardiomyopathy in mice
por: Voit, Antanina, et al.
Publicado: (2017)

Cardiomyopathy as cause of death in Duchenne muscular dystrophy: a longitudinal observational study
por: Lechner, Annabel, et al.
Publicado: (2023)

Beta‐blockers for hypertension
por: Wiysonge, Charles S, et al.
Publicado: (2017)

Beta-blockers in sepsis
por: Singer, Mervyn
Publicado: (2019)

Beta Blockers and Melanoma
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

The role of fibrosis in Duchenne muscular dystrophy
por: KLINGLER, WERNER, et al.
Publicado: (2012)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Targeting angiogenesis in Duchenne muscular dystrophy
por: Podkalicka, Paulina, et al.
Publicado: (2019)

Regenerative biomarkers for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

Nutritional Challenges in Duchenne Muscular Dystrophy
por: Salera, Simona, et al.
Publicado: (2017)

Lifetime Care of Duchenne Muscular Dystrophy
por: MacKintosh, Erin W., et al.
Publicado: (2020)

The Duchenne muscular dystrophy gene and cancer
por: Jones, Leanne, et al.
Publicado: (2020)

CRISPR Therapeutics for Duchenne Muscular Dystrophy
por: Erkut, Esra, et al.
Publicado: (2022)

Gene Therapy for Duchenne Muscular Dystrophy
por: Elangkovan, Nertiyan, et al.
Publicado: (2021)

Family reflections: Duchenne Muscular Dystrophy
por: Gill, Omaira
Publicado: (2022)

Cardiac therapies for Duchenne muscular dystrophy
por: Shah, Md Nur Ahad, et al.
Publicado: (2023)

The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study
por: Luño, José, et al.
Publicado: (2017)

Newborn screening for Duchenne muscular dystrophy‐early detection and diagnostic algorithm for female carriers of Duchenne muscular dystrophy
por: Gruber, Dorota, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vicd62jvu8snfgqabbkmmheb73